Evidence map›Paper›PMID 26567794›Full record

ArticleInvestigative ophthalmology & visual science2015

Intravitreal Ciliary Neurotrophic Factor Transiently Improves Cone-Mediated Function in a CNGB3-/- Mouse Model of Achromatopsia.

Dario Marangoni, Camasamudram Vijayasarathy, Ronald A Bush, Lisa L Wei, Rong Wen, Paul A Sieving

Open access · bronzeAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Gene therapy in color vision deficiency: a review.International ophthalmology · 2021
    Review
  4. Article
  5. Trans-ocular Electric CurrentMolecular therapy. Methods & clinical development · 2019
    Article
  6. A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Dario MarangoniNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, United States 3Department of Biotechnology and Applied Clinical Science, University of L'Aquila, L'Aquila, Italy.
Camasamudram VijayasarathyNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, United States.
Ronald A BushNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, United States.
Lisa L WeiNational Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Rong WenBascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miller School of Medicine, Miami, Florida, United States.
Paul A SievingNational Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, United States 2National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
National Institute on Deafness and Other Communication Disorders · USNational Eye Institute · USNational Institutes of Health · USUniversity of L'Aquila · ITUniversity of Miami · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

purposeCiliary neurotrophic factor (CNTF) was recently shown to augment cone function in CNGB3 mutant achromat dogs. However, testing CNTF-releasing implant in human CNGB3 achromats failed to show benefit. We evaluated the effects of CNTF protein on the retinal function in an additional achromatopsia model, the CNGB3-/- mouse.

methodsFifty-nine CNGB3-/- mice (postnatal day [PD] ± SD = 30 ± 7) received a unilateral intravitreal injection of 1 or 2 μg CNTF protein, and 15 wild-type (WT) mice (PD = 34 ± 3) received 1 μg CNTF. Retinal function was evaluated by flash ERG and photopic flicker ERG (fERG) at 7 and 14 days after treatment.

resultsSeven days post CNTF, the photopic b-wave Vmax was significantly increased in CNGB3-/- mice (P < 0.01), whereas it was reduced in WT mice (P < 0.05). Ciliary neurotrophic factor significantly increased the amplitude of photopic fERG and the photopic oscillatory potentials (OPs) in CNGB3-/- mice. Ciliary neurotrophic factor did not alter the scotopic a-wave in either CNGB3-/- or WT mice, but it increased the scotopic b-wave k (P < 0.01) in CNGB3-/- mice, indicating diminished scotopic sensitivity, and reduced the scotopic b-wave Vmax in WT mice (P < 0.05). No difference was found in ERG parameters between 1 or 2 μg CNTF. Fourteen days after CNTF injection the ERG changes in CNGB3-/- mice were lost.

conclusionsIntravitreal bolus CNTF protein caused a small and transient improvement of cone-mediated function in CNGB3-/- mice, whereas it reduced rod-mediated function. The increase in photopic OPs and the lack of changes in scotopic a-wave suggest a CNTF effect on the inner retina.

Indexed as

AnimalsCiliary Neurotrophic FactorColor Vision DefectsDisease Models, AnimalDrug ImplantsElectroretinographyIntravitreal InjectionsMiceMice, TransgenicRetinal Cone Photoreceptor CellsCiliary Neurotrophic FactorDrug Implants

Identifiers

PMID26567794
PMCPMC4627357
OpenAlexW2173642470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.